#mentalhealthawarenessweek: International Biotechnology Trust highlights two companies bucking the trend

by | May 12, 2021

biotechnology

Marek Poszepczynski, joint lead investment manager of International Biotechnology Trust comments:

“There are a number of companies working to address mental health, which remains a high unmet medical need. For disease areas such as schizophrenia and major depression, there is an increased focus upon mental health especially after the impact of the pandemic and lockdowns.

 

“Looking at companies in IBT’s portfolio, Sage Therapeutics and Intra-Cellular Therapies are two examples of such companies that have candidate treatments for mental health diseases.  The former is set to read out phase 3 trials in major depression imminently. Intra-Cellular has recently received approval for Caplyta, a treatment for negative symptoms of schizophrenia and the drug is in late stage trials to investigate its effect in major depression. Unlike oncology, for example, mental health therapeutics have not had the same pace of scientific breakthroughs but these two companies are bucking the trend with their potential treatments.“

 

Related articles

UK recession confirmed but economy shows signs of steadying

UK recession confirmed but economy shows signs of steadying

Following the publication of their revised estimate of Q4 2023 UK GDP from the ONS might we dare to believe that there be brighter times ahead? Lindsay James, investment strategist at Quilter Investors, has shared her reaction to the news with us as follows: "While...

Will uranium continue to glow for investors?

Will uranium continue to glow for investors?

Written by Thomas Roderick, Portfolio manager, Trium Epynt Macro Fund Uranium has been the standout commodity of the past 12 months - nearly doubling in price to $100 per pound, with nuclear firmly back on the policy agenda as part of the green energy transition. The...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x